Urology News and Research RSS Feed - Urology News and Research

Urology is the field of medicine that focuses on the urinary tracts of males and females, and on the reproductive system of males. In men, the urinary system overlaps with the reproductive system, and in women the urinary tract opens into the vulva. In both sexes, the urinary and reproductive tracts are close together, and disorders of one often affect the other. The organs covered by urology include the kidneys, ureters, urinary bladder, urethra, and the male reproductive organs (testes, epididymis, vas deferens, seminal vesicles, prostate and penis).
Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Robotic nephrectomy for inferior vena cava tumor thrombus shows promise in selected patients

Renal cell carcinoma can sometimes spread to the inferior vena cava (IVC), the body's largest vein, posing a threat to the heart and brain. Robotic nephrectomy for inferior vena cava tumor thrombus has favorable outcomes in selected patients compared with open surgery, which can have a high rate of complications, report surgeons in The Journal of Urology. [More]
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. [More]
Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan and AstraZeneca partner to develop, commercialize ATM-AVI for MBL-producing pathogens

Allergan plc today announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. [More]
Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan's investigational medication rapastinel granted FDA Breakthrough Therapy designation

Allergan plc., a leading global pharmaceutical company today announced that its Phase III ready investigational medication rapastinel (GLYX-13) received Breakthrough Therapy designation from the U.S. Food and Drug Administration for adjunctive treatment of Major Depressive Disorder (MDD). [More]
New prognostic biomarker may help determine risk of prostate cancer-related death

New prognostic biomarker may help determine risk of prostate cancer-related death

Researchers at the University of Copenhagen have identified a new prognostic biomarker: the neuropeptide pro-NPY, which may help determine the risk of dying from prostate cancer. This particular type of protein is very specific to prostate cancer cells and could help identify whether newly diagnosed patients require radical prostatectomy surgery or if it is safe to delay surgery. [More]
Upstate Medical University physicians use minimally invasive robotic surgery in complex IVC thrombus case

Upstate Medical University physicians use minimally invasive robotic surgery in complex IVC thrombus case

Physicians at Upstate Medical University in Syracuse describe in the December issue of Urology the first case ever in which doctors used minimally invasive robotic surgery to perform a radical nephrectomy (removal of entire kidney) with a level III inferior vena cava thrombectomy (removal of a tumor from the largest vein that carries blood to the heart). [More]
High intensity focused ultrasound provides important treatment for men with prostate cancer

High intensity focused ultrasound provides important treatment for men with prostate cancer

For the estimated 220,000 men who will be diagnosed with prostate cancer this year, deciding on a method of treatment can be a challenge. Some with early-stage cancer pursue a "wait and watch" option, also called active surveillance, while others with more severe cancer immediately pursue surgery, including prostatectomy (removal of the prostate). [More]
FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

FDA approves Allergan's sNDA to update label for DALVANCE (dalbavancin) for injection

Allergan plc, a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for DALVANCE (dalbavancin) for injection. [More]
Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine. [More]
Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Study provides evidence for use of inherited genetic markers to improve melanoma prognostication

Melanoma is the most dangerous and lethal form of skin cancer. But just how long will a patient survive following the removal of a melanoma tumor? A more definitive answer to that question could come from new studies at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center. Researchers there have discovered an inherited genetic marker that might provide clinicians with a personalized tool to gauge an individual's survival and determine which patients require closer monitoring in the years following surgery. [More]
New imaging test detects prostate cancer much better than any other tests in use today

New imaging test detects prostate cancer much better than any other tests in use today

Researchers at Thomas Jefferson University have found the method they developed to image the prostate appears to be much better at detecting prostate cancer than any other test — radiographical, biopsy or blood — in use today. [More]
Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment

Rapastinel demonstrates pro-cognitive benefits in animal model of cognitive impairment

Allergan plc, a leading global pharmaceutical company, announced today that new data on the investigational medication rapastinel (GLYX-13) and its lack of impairment on cognitive function were published in the peer-reviewed journal Behavioural Brain Research. [More]
UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

UM SOM to team up with industry to develop vaccine for preventing deadly bacterial infections

The Center for Vaccine Development at the University of Maryland School of Medicine will participate in a partnership with industry to develop a vaccine to prevent a group of deadly bacterial infections that occur commonly among hospital patients. [More]
DNA-binding protein acts like genetic traffic signal to orchestrate early stage embryonic development

DNA-binding protein acts like genetic traffic signal to orchestrate early stage embryonic development

New research by UC San Francisco stem cell biologists has revealed that a DNA-binding protein called Foxd3 acts like a genetic traffic signal, holding that ball of undifferentiated cells in a state of readiness for its great transformation in the third week of development. [More]
Study supports argument that declining PSA screening may lead to avoidable cancer deaths

Study supports argument that declining PSA screening may lead to avoidable cancer deaths

The U.S. Preventive Services Task Force recommendation against regular prostate specific antigen (PSA) screening for prostate cancer (PCa) has been in place for two and a half years. Although the number of prostate needle biopsies (PNB) has been reduced, patients who undergo PNB are significantly more likely to be diagnosed with high risk disease, and detection of intermediate risk, potentially curable PCa has likely decreased. [More]

Income disparities persist between male and female urologists

Although the field of urology remains largely male dominated, the proportion of female physicians specializing in urology has increased from less than 0.5% in 1981 to 10% today, and 33% of students entering urology internships and residency programs are now female. [More]
African American men with prostate cancer have significantly lower PSA density than Caucasian men

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs. [More]

United Medical Systems to acquire USMD’s lithotripsy division

USMD Holdings, Inc., a physician-led integrated healthcare system, announces that it has entered into a definitive agreement to sell most of its lithotripsy division to United Medical Systems (UMS), a leading provider of mobile medical equipment and services, including urology, women's health and MRI imaging, to hospitals, surgery centers and physician offices across the U.S., Canada and South America. [More]
Patient's mental health prior to radical cystectomy can influence postoperative outcomes

Patient's mental health prior to radical cystectomy can influence postoperative outcomes

A patient's mental health prior to surgery can influence postoperative outcomes. Removal of the bladder, or radical cystectomy (RC), is an effective treatment for locally advanced bladder cancer, but complications occur in as many as 66% of patients. [More]
Discovery could pave way for targeted therapies to treat penile cancer

Discovery could pave way for targeted therapies to treat penile cancer

Researchers have identified potential genetic alterations in penile cancer that could pave the way for targeted treatments. [More]
Advertisement
Advertisement